TNF and COVID-19: An analysis of data from various registry-based and national cohort studies suggests that patients with axSpA, particularly those receiving TNF-α inhibitor monotherapy, do not face an increased risk of hospitalization or mortality due to COVID-19 [17,42,43,44,45,46].